HPRA and peptide imports in Ireland

The short answer

There is no single answer, because "peptides" covers two categories that Irish law treats very differently. A peptide sold as a laboratory reagent, labelled research-use-only and carrying no medical claims, is handled as a laboratory chemical. A peptide that is an authorised medicine, or that is marketed with human dosing and weight-loss claims, falls under medicines law. The same molecule can sit on either side of that line depending on how it is sold.

The regulator: the HPRA

Medicines in Ireland are regulated by the Health Products Regulatory Authority, the HPRA, which authorises, monitors and enforces medicines law. Its site is hpra.ie. The relevant national instrument is the Medicinal Products (Control of Placing on the Market) Regulations, which implements the EU medicines framework in Irish law.

One point matters more than any other and is often left out: supplying prescription medicines online into or within Ireland is illegal. That is not a grey area and it does not depend on the buyer's intentions.

Medicinal peptide versus research reagent

• Medicinal peptides. Authorised as medicines, prescription-only, and supplied through the pharmacy channel. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the obvious examples. These are not general-sale products in Ireland under any framing.
• Research reagents. Laboratory chemicals labelled for research use only, sold without medical claims, without human dosing guidance, and not presented as a treatment for anything. This is the category the compounds on this site are sold in.

The distinction is not a labelling trick that makes any compound acceptable. It is a real difference in what is being sold and to whom, and enforcement cases turn on exactly that: whether the seller made weight-loss claims, whether human dosing schedules were published, and whether supply was to research users or to the general public.

What the enforcement figures actually show

This is the part worth reading carefully, because it describes what is happening now rather than what the rules say in principle.

• Items claiming to be a GLP-1 medicine detained by the HPRA rose from 1,582 in 2024 to 48,752 in 2025, a thirty-fold increase.
• The HPRA detained just under 14,000 individual packages in 2025, each one linked to a separate purchase by a member of the public. That is a 180 percent rise year on year.
• More than 750,000 dosage units of falsified and illegal medicines were detained in total.
• Most of the detained GLP-1 items were drops (27,329) and microneedle patches (17,170). When the HPRA tested a sample of the patches, they did not contain semaglutide at all.

Two things follow from that. First, personal parcels are being stopped, and at a rapidly rising rate. Second, a large share of what people were buying was not the compound on the label, which is the practical argument for batch documentation over marketing copy.

Ireland is in the EU, and that changes one thing but not another

A shipment from another EU member state, Lithuania for example, moves inside the single market. There is no customs declaration and no import duty. Ireland's position outside the Schengen area is a border-control arrangement and has no bearing on goods moving in the customs union.

What intra-EU status does not do is change medicines law. A product that is an unauthorised medicine remains one regardless of which member state posted it. Free movement of goods and the medicines framework are separate questions, and conflating them is the most common error on pages covering this topic.

If a shipment is queried

The recipient is normally contacted and asked for documentation. For a genuine laboratory reagent that means three things: the commercial invoice, the certificate of analysis for the specific batch, and the correct commodity code. Complete paperwork answered promptly is the ordinary path. Where a product is assessed as an unauthorised medicine, it is detained rather than released, and no amount of paperwork changes that assessment.

The narrow personal-import route

Irish law does provide a limited route for importing an unapproved medicine for personal use, but it is narrower than it is often described. In broad terms the quantity must not exceed a three-month supply, it must be for the importer's own use, and a valid prescription from a registered medical practitioner is required. A supporting letter from the prescriber explaining why no authorised alternative is available may also be needed. This exists for patients with a genuine clinical need, not as a general import channel.

Where information ends and a prescription begins

This is a summary of a regulatory framework, not legal advice, and it is not a route map for obtaining a prescription medicine outside the pharmacy channel. If your question is about treating a person, the answer is a doctor and a pharmacy, not a research supplier. If your question is about laboratory work, the compound documentation and the batch certificate are the things worth checking first.

Frequently asked questions

Continue

Sources: Health Products Regulatory Authority enforcement reporting for 2025, and the Medicinal Products (Control of Placing on the Market) Regulations. Figures cited are those published by the HPRA.